The only provision I know of in the Inflation Reduction Act that applies to lower drug costs is the limit on costs per month for Medicare patients requiring insulin. If a biotech firm brings out a new treatment, whether for diabetes, cancer, heart disease, etc., the chance for this new (often very expensive) drug to be more affordable actually increases. For more than 50 years, every time new legislation makes medical treatment more affordable for large sectors of the population (Medicaid, Medicare, prescription coverage), drug firms make more money, not less, because the addressable market increases substantially.
Art |
